In a milestone development for cardiovascular medicine, Cytokinetics has announced positive topline results from the Phase III ACACIA-HCM trial. The study, which investigated the efficacy and safety of the selective cardiac myosin inhibitor aficamten in patients with nonobstructive hypertrophic cardiomyopathy (HCM), has met its dual primary endpoints. If approved by global regulatory bodies, this therapeutic could become the first-ever pharmacological treatment specifically indicated for the nonobstructive form of this complex heart disease.
The findings offer a glimmer of hope for a patient population that has historically faced limited treatment options compared to their counterparts with obstructive HCM. By demonstrating significant improvements in both symptomatic burden and objective exercise capacity, aficamten appears to have cleared a hurdle that previous agents, most notably mavacamten, failed to surmount.
The Clinical Landscape: Addressing an Unmet Need
Hypertrophic cardiomyopathy is a condition characterized by the thickening of the heart muscle, which can impede the organ’s ability to pump blood effectively. While obstructive HCM—caused by a physical blockage of blood flow—has seen significant innovation with the advent of cardiac myosin inhibitors, the nonobstructive variant has remained notoriously difficult to treat.
For years, clinicians have been forced to rely on supportive care, such as beta-blockers or calcium channel blockers, to manage symptoms like shortness of breath and fatigue. Despite these therapies, many patients continue to suffer from severe physical limitations and a diminished quality of life. The ACACIA-HCM trial was designed specifically to determine if modulating the heart’s contractile mechanism via aficamten could provide a more targeted therapeutic approach.
Chronology of the ACACIA-HCM Trial
The road to these positive results was meticulously structured to ensure data integrity and patient safety.
- Study Enrollment and Design: The ACACIA-HCM trial enrolled 516 symptomatic patients. The trial design employed a flexible dosing strategy, starting participants on 5 mg of aficamten once daily.
- Dose Optimization: To maximize efficacy while prioritizing safety, the protocol allowed for dose escalation up to 20 mg. This escalation was contingent upon rigorous echocardiographic monitoring to ensure no adverse impact on left ventricular ejection fraction (LVEF).
- The 36-Week Benchmark: After 36 weeks of treatment, researchers evaluated the dual primary endpoints: the Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score and maximal exercise performance.
- Long-Term Follow-up: Beyond the primary 36-week analysis, participants were monitored through an extended 72-week follow-up period.
- Open-Label Transition: Upon the completion of the study, the vast majority of participants opted to transition into an open-label registry to continue receiving the treatment and provide long-term safety data.
Supporting Data: By the Numbers
The statistical significance of the ACACIA-HCM data provides a compelling argument for the drug’s utility in a nonobstructive population.
Symptomatic Improvement
The KCCQ clinical summary score is a gold-standard metric for assessing physical limitations and symptom burden. In the trial, both the treatment and placebo arms saw improvements; however, the aficamten group experienced a statistically superior benefit. The least squares mean improvement was 11.4 in the aficamten arm compared to 8.4 in the placebo arm, yielding a P-value of 0.021.
Exercise Capacity
Peak oxygen consumption—a key indicator of cardiovascular fitness and functional health—showed a distinct divergence between the two groups. Patients receiving aficamten experienced a mean increase of 0.64 mL/kg/min, while those in the placebo group saw a slight decrease of 0.03 mL/kg/min (P = 0.003).
Secondary Outcomes
Beyond the primary endpoints, the drug demonstrated a favorable impact on critical secondary metrics, including:
- NYHA Functional Class: A significant shift toward better functional status.
- NT-proBNP: Reductions in this biomarker, which serves as a proxy for cardiac wall stress and heart failure severity, were noted, suggesting that the treatment is reducing underlying cardiac strain.
Safety Profile and Clinical Vigilance
The clinical success of aficamten must be weighed against its safety profile, particularly regarding the risk of systolic dysfunction. As is common with cardiac myosin inhibitors, the drug carries a boxed warning regarding the potential for reduced LVEF.
In the ACACIA-HCM trial, 10% of patients treated with aficamten experienced an LVEF reduction below 50%, compared to only 1% in the placebo group. Notably, 3% of the treatment cohort discontinued the drug due to an LVEF dropping below 40%. Furthermore, two patients experienced serious heart failure events linked to reduced ejection fraction.
Cytokinetics leadership addressed these findings during an investor call, emphasizing that the monitoring strategy is part of the clinical "trade-off" when employing a high-dose titration strategy. Dr. Fady Malik, MD, PhD, Cytokinetics’ Executive Vice President, noted that these findings were not unexpected given the study’s protocol, which prioritized achieving a "maximally tolerated dose" to ensure the highest possible therapeutic benefit.
Official Responses and Strategic Implications
The success of ACACIA-HCM stands in stark contrast to the results of the ODYSSEY-HCM trial, which previously failed to show significant improvement in nonobstructive HCM patients using mavacamten. This disparity highlights the potential for distinct pharmacokinetic or pharmacodynamic advantages in aficamten’s profile.
The Regulatory Path
Cytokinetics is currently preparing the full dataset for submission to regulatory authorities, including the FDA. Should the results hold up under the scrutiny of the regulatory review process, aficamten would represent a landmark approval in cardiovascular medicine. It would provide the first evidence-based pharmacological intervention for a group of patients who have historically been left behind by clinical innovation.
The Clinical Impact
For the cardiology community, these results suggest that the "nonobstructive" label is no longer a dead end for myosin inhibitor therapy. If the drug receives approval, it will likely necessitate a shift in how cardiologists approach the management of HCM. The emphasis will move toward a more precise, monitored administration of myosin inhibitors, requiring clinics to maintain robust echocardiography protocols to ensure patient safety.
Future Outlook: Looking Beyond the Data
While the scientific community awaits the presentation of the full dataset at an upcoming major cardiology meeting, the current topline results are being viewed with cautious optimism. The consistency of the results—from the 8-week mark through the 72-week follow-up—suggests that the improvements in quality of life are durable.
The success of ACACIA-HCM serves as a poignant reminder of the importance of persistent clinical research. By revisiting the nonobstructive patient population with a different molecule and a refined dosing strategy, Cytokinetics has managed to unlock a therapeutic pathway that many had written off as impossible.
As we look toward the future, the focus will remain on long-term safety and the potential for these drugs to alter the natural history of the disease. For the thousands of patients living with the physical, emotional, and social toll of nonobstructive HCM, the potential arrival of aficamten offers more than just statistics; it offers the prospect of a more active, symptom-free life.
Reporting by Michael O’Riordan, TCTMD. This article is intended for informational purposes and does not constitute medical advice.
